Drug intelligence / Profile preview

petesicatib

Development stage: Phase 2
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

Petesicatib is a small molecule, orally administered cathepsin S inhibitor that was developed by Roche for the treatment of autoimmune diseases, including coeliac disease, psoriasis, and Sjogren's syndrome. Cathepsin S is a thiol protease involved in antigen presentation via MHC class II molecules and plays a key role in immune system regulation. By inhibiting cathepsin S, petesicatib modulates immune responses relevant to autoimmune pathology. The drug reached phase II clinical trials but development was discontinued for all indications[1][2][3][4][5].

Other names: petesicatib1252637-35-6

Targets

CTSS (Cathepsin S)

Beyond the preview

Go deeper on petesicatib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on petesicatib.

Explore the full profile